Logo image of CRGX

CARGO THERAPEUTICS INC (CRGX) Stock Fundamental Analysis

NASDAQ:CRGX - Nasdaq - US14179K1016 - Common Stock - Currency: USD

4.6  0 (0%)

After market: 4.6 0 (0%)

Fundamental Rating

2

Overall CRGX gets a fundamental rating of 2 out of 10. We evaluated CRGX against 568 industry peers in the Biotechnology industry. While CRGX has a great health rating, there are worries on its profitability. CRGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRGX had negative earnings in the past year.
CRGX had a negative operating cash flow in the past year.
CRGX Yearly Net Income VS EBIT VS OCF VS FCFCRGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CRGX has a Return On Assets of -40.45%. This is comparable to the rest of the industry: CRGX outperforms 56.16% of its industry peers.
CRGX's Return On Equity of -46.50% is fine compared to the rest of the industry. CRGX outperforms 67.08% of its industry peers.
Industry RankSector Rank
ROA -40.45%
ROE -46.5%
ROIC N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRGX Yearly ROA, ROE, ROICCRGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRGX Yearly Profit, Operating, Gross MarginsCRGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, CRGX has more shares outstanding
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRGX Yearly Shares OutstandingCRGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
CRGX Yearly Total Debt VS Total AssetsCRGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.74, we must say that CRGX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.74, CRGX is in the better half of the industry, outperforming 67.61% of the companies in the same industry.
There is no outstanding debt for CRGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.74
ROIC/WACCN/A
WACCN/A
CRGX Yearly LT Debt VS Equity VS FCFCRGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 13.79 indicates that CRGX has no problem at all paying its short term obligations.
CRGX has a Current ratio of 13.79. This is amongst the best in the industry. CRGX outperforms 87.50% of its industry peers.
CRGX has a Quick Ratio of 13.79. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 13.79, CRGX belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.79
Quick Ratio 13.79
CRGX Yearly Current Assets VS Current LiabilitesCRGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

CRGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.38%.
EPS 1Y (TTM)-56.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRGX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.38% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.76%
EPS Next 2Y10.73%
EPS Next 3Y9.44%
EPS Next 5Y5.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRGX Yearly Revenue VS EstimatesCRGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
CRGX Yearly EPS VS EstimatesCRGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRGX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRGX Price Earnings VS Forward Price EarningsCRGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRGX Per share dataCRGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.73%
EPS Next 3Y9.44%

More info and screens

0

5. Dividend

5.1 Amount

CRGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARGO THERAPEUTICS INC

NASDAQ:CRGX (4/22/2025, 8:00:00 PM)

After market: 4.6 0 (0%)

4.6

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-12 2025-05-12
Inst Owners113.88%
Inst Owner Change0.01%
Ins Owners0.24%
Ins Owner Change12.72%
Market Cap211.83M
Analysts49.09
Price Target10.89 (136.74%)
Short Float %8.03%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.42%
Min EPS beat(2)3.09%
Max EPS beat(2)23.75%
EPS beat(4)4
Avg EPS beat(4)12.13%
Min EPS beat(4)2.64%
Max EPS beat(4)23.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.72%
PT rev (3m)-66.49%
EPS NQ rev (1m)7.25%
EPS NQ rev (3m)28.08%
EPS NY rev (1m)-13.76%
EPS NY rev (3m)34.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-3.72
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS0
BVpS7.82
TBVpS7.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.45%
ROE -46.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 167.37%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.79
Quick Ratio 13.79
Altman-Z 0.74
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)467.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.24%
EPS Next Y25.76%
EPS Next 2Y10.73%
EPS Next 3Y9.44%
EPS Next 5Y5.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.17%
OCF growth 3YN/A
OCF growth 5YN/A